4.8 Article

Regulatory T-cell therapy in Crohn's disease: challenges and advances

Journal

GUT
Volume 69, Issue 5, Pages 942-952

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2019-319850

Keywords

-

Funding

  1. Litwin IBD Pioneers Funding Programme at the Crohn's and Colitis Foundation [504039]
  2. Freemason's Grand Charity [SPG00268]
  3. Rosetree's Trust [A1219]
  4. Medical Research Council (MRC) Trust Clinical Research Training Fellowship [MRS00033X/1]
  5. MRC [MR/R001413/1, MR/T005564/1]
  6. Department of Health via the National Institute for Health (NIHR) comprehensive Biomedical Research Centre
  7. King's College London
  8. King's College Hospital NHS Foundation Trust
  9. MRC [G0802068, MR/M003493/1, MR/N006445/1, MR/S00033X/1, MR/T005564/1] Funding Source: UKRI

Ask authors/readers for more resources

The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available